What we’re watching in Washington: health care and ag policy
With the 118th Congress picking up steam, the Biotechnology Innovation Organization’s (BIO) Federal…
Pfizer Ignite’s new model is turning heads and sharing the wealth
“It’s exciting times,” said Kathy Fernando, Senior Vice President and Global Head of…
Investment in new pain and addiction treatments falls short, says BIO study
David Thomas and Chad Wessel of the Biotechnology Innovation Organization’s (BIO) Industry Analysis…
How to follow the BIO CEO and Investor Conference 2023
The teams behind Good Day BIO and Bio.News is live at the BIO…
Draft WHO pandemic treaty suggests future IP waivers
The World Health Organization (WHO) suggests additional waivers of intellectual property rights during…
BIO recommends 11 countries for USTR’s Priority Watch List
The intellectual property protections that enabled the record-setting development of COVID-19 vaccines and…
EDITORS’ CHOICE
How to follow the BIO CEO and Investor Conference 2023
The teams behind Good Day BIO and Bio.News is live at the BIO CEO and Investor Conference in New York….
Read more
Latest News
What we’re watching in Washington: health care and ag policy
With the 118th Congress picking up steam, the Biotechnology Innovation Organization’s (BIO) Federal Government Relations team shared what to expect…
Pfizer Ignite’s new model is turning heads and sharing the wealth
“It’s exciting times,” said Kathy Fernando, Senior Vice President and Global Head of the Partner of Choice Organization at Pfizer…
Investment in new pain and addiction treatments falls short, says BIO study
David Thomas and Chad Wessel of the Biotechnology Innovation Organization’s (BIO) Industry Analysis team, authors of The State of Innovation…
How to follow the BIO CEO and Investor Conference 2023
The teams behind Good Day BIO and Bio.News is live at the BIO CEO and Investor Conference in New York….
Draft WHO pandemic treaty suggests future IP waivers
The World Health Organization (WHO) suggests additional waivers of intellectual property rights during the next pandemic in the initial draft…
HEALTH
COVID-19 forced us to reimagine pharma supply chains – and that’s a good thing.
BIO’s Chief Policy Officer John Murphy joined a panel hosted by The Hill to discuss how the pandemic affected drug supply chains and the opportunity to improve them going forward.
AGRICULTURE
CLIMATE CHANGE
What we’re watching in Washington: health care and ag policy
With the 118th Congress picking up steam, the Biotechnology Innovation Organization’s (BIO) Federal Government Relations team shared what to expect…
Read more
FEDERAL POLICY
STATE POLICY
2022 midterms recap: what happened and what the results mean for biotech
The 2022 midterms are officially behind us – so, what happened, and what does biotech need to know going into…
Read more
INTERNATIONAL
!["[...] Price controls reduce access to treatments and cures.” — The Wall Street Journal Editorial Board](https://wp.bio.news/wp-content/uploads/2023/01/Antibiotics-1-350x250.jpg)
BIO’s VIEW
How to follow the BIO CEO and Investor Conference 2023
The teams behind Good Day BIO and Bio.News is live at the BIO CEO and Investor Conference in New York….
Read more
